News | Heart Failure | December 16, 2021

First-Of-Its-Kind Medicare Advantage Plan Addresses Diabetics With Heart Failure

New York and Vermont plan is one of three plans in the country to offer free, level 3 cardiac rehab

First-Of-Its-Kind Medicare Advantage Plan Addresses Diabetics With Heart Failure. Getty images

Getty images


December 16, 2021 — MVP Health Care and The University of Vermont Health Network recently announced their joint Medicare Advantage Plan, called UVM Health Advantage, will offer older adults in Northern New York and Vermont support for their two biggest health concerns: heart disease and diabetes. The plan provides 3 months of free medically tailored meals for those diagnosed with congestive heart failure, up to 36 free rides to or from medical appointments, a digital blood pressure cuff and pulse oximeter, low-cost orthotics and diabetic shoes, and more. Members of UVM Health Advantage will also have access to MVP’s vast network of physicians across Vermont and New York.

“UVM Health Advantage delivers a completely new Medicare Advantage experience – one that’s simpler, easier to use, and designed with our members and their physicians,” said MVP Health Care’s president and Chief Executive Officer, Christopher Del Vecchio. “We’re proud to pioneer this vision in partnership with UVM Health Network, which offers bold options for fighting two wide-spread conditions that older adults are facing.”

According to the CDC, heart disease is the leading cause of death in New York and Vermont, which is why UVM Health Advantage is supporting older adults as they navigate their health journey against this condition. Cardiac rehab level 3, which is designed to maintain a healthier lifestyle through supervised exercise sessions and health education, is covered at no cost — one of only three insurance plans in the country to so. Additionally, studies have shown the link between good dental hygiene and cardiac care — which is why UVM Health Advantage also offers robust dental benefits to its members.

Diabetes was also a top concern among older adults in the region, as more than 1.7 million New Yorkers and more than 55,000 Vermonters have been diagnosed with the condition. UVM Health Advantage covers routine podiatry visits, provides a glucometer and related supplies, includes low-cost orthotics and diabetic shoes, and free gym memberships to support in living a healthier lifestyle.

“We know that heart disease and diabetes can be successfully managed if patients have the right tools and support they need,” said John R. Brumsted, M.D., president and CEO of The University of Vermont Health Network. “We are excited about our partnership with MVP to offer a plan that can help older adults in our region live healthier lives.”

For more information: www.uvmhealthadvantage.com


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now